131 HARTWELL AVENUE, LEXINGTON, MA
Other Events
Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
Chief Development Officer Resignation - Stephen G. Machatha Steps Down
Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
Investor Presentation
Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
FY 2024
Q3
Q2
Q1
Amended Annual Report
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
S-8 POS
Confidential Treatment Order